This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
As a result, the DEA has been encouraged for over a decade to expand the pool of federally licensed cannabis producers — a move that the agency has largely resisted. To date, however, the DEA has failed to either affirm or reject any of the more than 30 applications it has received. In 2007, the agency lost yet another lawsuit.
” Last year, however, former DEA director Robert Patterson testified to Congress that the agency believed that approving additional applicants would likely violate international anti-drug treaties. Patterson said that DEA could not move forward granting any new applications until the Justice Department clarified the issue.
Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA). By Allison Campbell.
we want everyone who did not have the opportunity to attend Meadowlands to have access to this content. Back in 2007, it said we don’t want anymore cannabis businesses and despite a general prohibition, we still had more cannabis businesses than any other location. So in L.A., we know you have a cap for 400 retail locations.
Later that year, Doblin sued the DEA for the first time. submitted his first DEA application to manufacture marijuana for use in medical research. To celebrate this, we invite you to take a trip down memory lane and review highlights from every year of our history. Lyle Craker, Ph.D., MAPS Founder Rick Doblin, Ph.D.,
The DEA has made previous requests–in 2001 and 2006–to the FDA for an evaluation of marijuana. But DEA regulators determined after both of those reviews that marijuana should remain a Schedule I substance. 2003, 2004, 2007, 2008, Nov. 2003, 2004, 2007, 2008, Nov. 6059, 6074, 6075, 6077(a), (b), 6253, Nov.
In 2007, he acknowledged that ending raids on medical marijuana users was necessary, but that he believed that “there’s got to be a better answer than marijuana” for addressing health issues and symptoms. Only marijuana-friendly people will be assigned to DEA, DOJ, and FDA to get involved in the legalization process. Tulsi Gabbard Rep.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content